State Street Holds 4% Of Corvus As The Drug Developer's Trial Bill Grows

Corvus expects its cash to last into the second quarter of 2028, with a lymphoma-study assessment expected in early 2027.

Share
State Street Holds 4% Of Corvus As The Drug Developer's Trial Bill Grows

State Street reported a 4% stake in Corvus Pharmaceuticals, which develops experimental treatments for immune diseases and cancer, in a passive ownership disclosure filed Tuesday. The position covered 3,331,535 shares as of September 30, 2026, while Corvus's third-quarter research bill rose to $17.8 million from $8.5 million a year earlier.

A Passive Position, Not A Control Bid

State Street said it held the investment for ordinary business purposes, rather than to change or influence Corvus's control. The 4% figure measures its beneficial ownership of the common-stock class.

State Street had shared voting power over 3,233,973 shares and no sole voting power. It also reported shared power to dispose of 3,331,535 shares. Those holdings describe the September 30 position, not an investment made on Tuesday.

Corvus's market value was $957 million as of 7:12 a.m. ET Tuesday.

Trials Drive A Larger Research Bill

Corvus Chief Financial Officer Leiv Lea put third-quarter research spending at $17.8 million, versus $8.5 million a year earlier. The company attributed the increase to personnel and trial costs across its work in lymphoma, atopic dermatitis, hidradenitis suppurativa and asthma.

Its quarterly net loss widened to $20.3 million from $10.2 million a year earlier. Corvus had $202.9 million in cash at September 30 and expects that money to fund operations into the second quarter of 2028, beyond its expected late-stage lymphoma results.

The company's lead drug candidate, soquelitinib, is being tested in a late-stage trial for relapsed peripheral T cell lymphoma. It also began a mid-stage atopic dermatitis trial in March 2026. Corvus's other candidates, ciforadenant and mupadolimab, target solid tumors.

Corvus has no drugs approved for sale. It relies on outside contract manufacturers rather than owning manufacturing facilities, and its development work targets proteins involved in immune-cell maturation and function.

Corvus expects a first-quarter 2027 assessment of its late-stage lymphoma trial to determine whether the study should continue or stop because it is unlikely to succeed.

Sources

More on Corvus Pharmaceuticals

All Corvus Pharmaceuticals (CRVS) coverage →